Ferring Drug Patent Portfolio
Ferring owns 3 orange book drugs protected by 12 US patents Given below is the list of Ferring's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10695398 | Method of treating prostate cancer with GnRH antagonist | 27 Apr, 2032 | Active |
| US11766468 | Method of treating prostate cancer with GnRH antagonist | 27 Apr, 2032 | Active |
| US11826397 | Method of treating prostate cancer with GnRH antagonist | 27 Apr, 2032 | Active |
| US9415085 | Method of treating prostate cancer with GnRH antagonist | 27 Apr, 2032 | Active |
| US10729739 | Methods of treating prostate cancer with GnRH antagonist | 10 Feb, 2029 | Active |
| US10973870 | Methods of treating prostate cancer with GnRH antagonist | 10 Feb, 2029 | Active |
| US9579359 | Method of treating prostate cancer with GnRH antagonist | 10 Feb, 2029 | Active |
| US7022340 | Pharmaceutical composition as solid dosage form and method for manufacturing thereof | 30 Apr, 2023 | Expired |
| US5925730 | GnRH antagonists | 18 May, 2021 | Expired |
| US7300664 | Vaginally administrable progesterone-containing tablets and method for preparing same | 17 Nov, 2019 | Expired |
| US7320800 | Vaginally administrable progesterone-containing tablets and method for preparing same | 17 Nov, 2019 | Expired |
| US7393543 | Vaginally administratable progesterone-containing tablets and method for preparing same | 17 Nov, 2019 | Expired |
Latest Legal Activities on Ferring's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ferring.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Feb, 2024 | US9415085 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Jan, 2024 | US10729739 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Dec, 2023 | US10695398 |
|
Email Notification
Critical
| 29 Nov, 2023 | US11826397 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Nov, 2023 | US11826397 |
| Patent eGrant Notification | 28 Nov, 2023 | US11826397 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Nov, 2023 | US11826397 |
| Mail Patent eGrant Notification | 28 Nov, 2023 | US11826397 |
| Recordation of Patent eGrant | 28 Nov, 2023 | US11826397 |
|
Email Notification
Critical
| 09 Nov, 2023 | US11826397 |
|
Issue Notification Mailed
Critical
| 08 Nov, 2023 | US11826397 |
|
Application Is Considered Ready for Issue
Critical
| 19 Oct, 2023 | US11826397 |
| Dispatch to FDC | 19 Oct, 2023 | US11826397 |
|
Issue Fee Payment Received
Critical
| 18 Oct, 2023 | US11826397 |
|
Issue Fee Payment Verified
Critical
| 18 Oct, 2023 | US11826397 |
Ferring Drug Patents' Oppositions Filed in EPO
Ferring drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 23, 2015, by Generics (Uk) Ltd (Trading As Mylan). This opposition was filed on patent number EP09711390A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP13168404A | Dec, 2015 | Generics [UK] Ltd (trading as Mylan) | Revoked |
| EP13168404A | Dec, 2015 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP12165896A | Sep, 2015 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP12165896A | Sep, 2015 | Generics [UK] Limited (trading as Mylan) | Revoked |
| EP09711390A | Jan, 2015 | Generics (UK) Ltd (trading as Mylan) | Revoked |
Ferring's Family Patents
Ferring Drug List
Given below is the complete list of Ferring's drugs and the patents protecting them.
1. Desmopressin Acetate
Desmopressin Acetate is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7022340 | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
30 Apr, 2023
(1 year, 6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Desmopressin Acetate's drug page
2. Endometrin
Endometrin is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7300664 | Vaginally administrable progesterone-containing tablets and method for preparing same |
17 Nov, 2019
(5 years ago)
| Expired |
| US7320800 | Vaginally administrable progesterone-containing tablets and method for preparing same |
17 Nov, 2019
(5 years ago)
| Expired |
| US7393543 | Vaginally administratable progesterone-containing tablets and method for preparing same |
17 Nov, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Endometrin's drug page
3. Firmagon
Firmagon is protected by 8 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10695398 | Method of treating prostate cancer with GnRH antagonist |
27 Apr, 2032
(7 years from now)
| Active |
| US11766468 | Method of treating prostate cancer with GnRH antagonist |
27 Apr, 2032
(7 years from now)
| Active |
| US11826397 | Method of treating prostate cancer with GnRH antagonist |
27 Apr, 2032
(7 years from now)
| Active |
| US9415085 | Method of treating prostate cancer with GnRH antagonist |
27 Apr, 2032
(7 years from now)
| Active |
| US10729739 | Methods of treating prostate cancer with GnRH antagonist |
10 Feb, 2029
(4 years from now)
| Active |
| US10973870 | Methods of treating prostate cancer with GnRH antagonist |
10 Feb, 2029
(4 years from now)
| Active |
| US9579359 | Method of treating prostate cancer with GnRH antagonist |
10 Feb, 2029
(4 years from now)
| Active |
| US5925730 | GnRH antagonists |
18 May, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firmagon's drug page